Published on 13 Oct 2022 on FOX 19 Cincinnati
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
Former chairman of CareDx, Inc. and seasoned global industry executive with track record of...
3 Beaten-Down Stocks to Buy and Hold
With this in mind, we asked three Motley Fool contributors to pick beaten-down stocks to buy and ...
Why Shares of Keros Therapeutics Rose 10.2% This Week
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and...
Did The Texas ESG Ban Have Any Bite?
I tried to cross-tally the list of funds and companies banned by the Texas Comptroller with the p...
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
Former chairman of CareDx, Inc. and seasoned global industry executive with track record of...
Pfizer: An Excellent Combinati - GuruFocus.com
The decline in the share price is slightly ahead of the 23.64% decrease in the S&P 500 Index. Lea...
Gastrointestinal Stromal Tumors Therapeutics Market Size to Grow by USD 1.08 Bn, Growing Geriatric...
NEW YORK, Oct. 9, 2022 /PRNewswire/ -- The "Gastrointestinal Stromal Tumors Therapeutics Market b...
5 Stocks to Delete From Your Watchlist in Q4
Amid rising recession worries, we think fundamentally weak stocks, Advanced Micro Devices (AMD), ...
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Launched on 04/19/2011, the First Trust Small Cap Growth AlphaDEX ETF (FYC) is a passively manage...
Lennox-Gastaut Syndrome Treatment Market 2026, Rising Population With Risk Factors For LGS to Boost...
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- The lennox-gastaut syndrome treatment market size is expec...
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Denmark-based Novo Nordisk A/S NVO has one of the broadest diabetes portfolios in the industry. T...